Radio and PodcastLive Radio & PodcastsScience & Medicine
109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO Results
Karyopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein...
Related Episodes
Continue listening to more episodes from Breaking Biotech.
112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRA
Apr 21, 2022 - 00:43:59
111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich
Apr 1, 2022 - 00:28:19
108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD
Feb 7, 2022 - 00:37:28
106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!
Jan 9, 2022 - 00:42:53